Vaccine Equity for Africa

Communiqué

on the development of vaccines for the continent, and their end-to-end production in Africa
Today, on 27 August 2021, in the Pierre Boulez Hall of the Barenboim-Said-Akademie in Berlin, Germany, convened by kENUP Foundation,

the

Republic of Senegal
His Excellency President Macky Sall

Republic of Rwanda
His Excellency President Paul Kagame

Africa CDC
Director Dr John Nkengasong

European Commission
President Dr Ursula von der Leyen

took note of a presentation given by

BioNTech SE
CEO Prof. Dr Ugur Sahin

in the presence of

World Health Organization (WHO)
Regional Director for Africa Dr Matshidiso Rebecca Moeti

European Investment Bank (EIB)
President Dr Werner Hoyer

Mastercard Foundation
President & CEO Reeta Roy
Following a productive discussion,
in the presence of the above,
this technical

Communiqué

has been agreed upon by

**Institut Pasteur de Dakar**
Dr Amadou Alpha Sall, Directeur-General

**Rwanda Biomedical Centre**
Dr Sabin Nsanzimana, Director-General

**BioNTech SE**
Prof. Dr Ugur Sahin, CEO
1. BioNTech SE is developing vaccine candidates against Malaria and Tuberculosis based on its proprietary mRNA platform. As with any vaccine development, these R&D efforts may or may not be successful.

2. Any approved vaccine arising from this process shall be manufactured end-to-end\(^1\) on the African Continent for supply to the Member States of the African Union. To that purpose all required studies will be undertaken, and local capacities will be developed to ensure sustainability.

3. BioNTech SE has followed the guidance of the African Union and the Africa CDC on the prospective locations of the necessary manufacturing sites on the Continent, where they are expected to co-locate with WHO’s upcoming Vaccine Hubs.

4. BioNTech has started the evaluation of respective manufacturing capabilities with immediate effect, so that in the interim, if and until the novel Malaria and Tuberculosis vaccines become available upon successful development and approval, the Company’s COVID-19 vaccine can technically be manufactured on these envisioned manufacturing sites for supply to the Member States of the African Union.

5. On behalf of the African Union, under the joint leadership of the Africa CDC and the African Medical Agency under formation, receiving guidance from WHO and the European Medicines Agency (EMA), with support from the Mastercard Foundation, kENUP Foundation shall conceive a White Book summarizing commonly accepted regulatory stipulations required for the governance of such processes. These efforts will be aligned with the Team Europe

---

\(^1\) end-to-end: manufacturing of mRNA drug substance and subsequent formulation, together called *bulk drug product*, followed by aseptic fill & finish
initiative on manufacturing and access to vaccines, medicines and medical technologies (MAV+) led by the European Commission in collaboration with EU Member States.

6. While BioNTech SE expects to invest its corporate resources into the actual bulk drug product manufacturing technology, its African partners are expected to each build the infrastructure required and set up auxiliary services as well as to ensure that eligible fill & finish facilities can provide in-country services to BioNTech SE according to the manufacturer’s specifications.

7. Given the complex nature of the foreseen operations, Team Europe, together with other international partners, will jointly support its African partners in their efforts to build the necessary enabling environment (business systems, procurement structure, regulatory capacity, human resources, regional trade integration, logistics, supply chains, etc.), and consolidate demand.

8. Today’s meeting marks the initiation of separate, open-ended pre-contractual proceedings, to be convened by kENUP Foundation, between Rwanda Biomedical Centre, Institut Pasteur de Dakar, and BioNTech SE respectively, with the aim of signing a technical affidavit in 2021, allowing for deployment of formulated bulk product to local fill and finish upon regulatory validation. It is understood that the company is holding parallel conversations with potential partners in South Africa.

9. This Communiqué does not create any legal obligation or the incurrence of any undertaking or liability. As such, it does not represent any commitment regarding funding or any form of preferential treatment on the part of either signatory. Also, this Communiqué does not grant an exclusivity to any of the parties in any respect. For the avoidance of doubt, it is understood that any detailed commitments shall be laid down in separate agreements that may be entered into by the signatories by virtue of this Communiqué, and in accordance with the framework set forth here and today.